Different from the view of Dr. Bill Armstrong who focused on result from patch-clamp recordings, Dr. Stoop summarized the neuromodulatory effects of OT and VP in different brain regions with the help of OT/VP promoter-driven expression of fluorescent proteins and light-activated ion channels. This review highlighted OT/VP concerted, and at times opposite, effects on different aspects of behavior.


Questions and discussions:

1.      How to understand the “controlled rapid and local release of OT/VP in different brain areas”?

2.      At the 8th position, VP possesses an arginine and OT a leucine. How could this one amino acid determine the specific binding ability of VP and OT to different receptors?

3.      What are the basic functions of VP and OT throughout evolution?

4.      How do you understand “it is tempting to see VP as a “selfish” and OT as an “altruistic” peptide”? Isn’t it against the finding that “nasal OT spray increases the altruistic behaviors in the group but hostile behaviors between groups”?

5.      When mutations make prohormones accumulate in the ER, chaperone processes and unfolded protein response remain working normally or abnormally?

6.      What is the difference in intracellular calcium mobilization for the release of classical neurotransmitters and for neuropeptides?

7.      What is your understanding of the “primining” effect of intracellular calcium mobilization on OT/VP release?

8.      OT/VP has very short hald-life and their fragments are also functional. How to differentiate the effect of these nonapeptides from the fragments?

9.      In optogenetic activation of OT/VP release, what is the optimal parameter?

10.   Is there a better OTR receptor antagonist than atosiban?


2018-12-21 Literature analysis

Ron Stoop. Neuromodulation by Oxytocin and Vasopressin. Neuron 2012, 76(1): 142-159. Presented by Dongyang Li.

Add Time: